Maxim Group Reaffirms Hold Rating for Aclarion (NASDAQ:ACON)

Aclarion (NASDAQ:ACON)‘s stock had its “hold” rating restated by equities researchers at Maxim Group in a report issued on Friday,Benzinga reports.

Separately, Ascendiant Capital Markets dropped their target price on shares of Aclarion from $1.50 to $1.30 and set a “buy” rating on the stock in a report on Wednesday, November 27th.

Aclarion Trading Down 6.1 %

ACON traded down $0.01 during trading on Friday, reaching $0.11. 582,912 shares of the company’s stock were exchanged, compared to its average volume of 1,414,292. The firm has a fifty day moving average price of $0.18 and a two-hundred day moving average price of $0.23. Aclarion has a one year low of $0.11 and a one year high of $7.40.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.